Janssen Global Services LLC

DUBLIN--( BUSINESS WIRE )--The "Intranasal Drug Delivery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Intranasal Drug Delivery is estimated at US$59.1 Billion in 2023 and is projected to reach US$92.6 Billion by 2030, growing at a CAGR of 6.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the intranasal drug delivery market is driven by several factors, including advancements in delivery technologies, increasing prevalence of chronic and acute conditions requiring rapid intervention, and a growing preference for non-invasive administration methods among patients and healthcare providers. Technological innovations, such as improved formulations and novel delivery devices, enhance drug stability and absorption, expanding the range of treatable conditions. Additionally, demographic trends such as aging populations and rising incidences of conditions like Alzheimer's disease and Parkinson's disease fuel demand for more effective drug delivery systems. Consumer behavior shifts towards self-administration and home care, coupled with healthcare cost containment strategies, further propel market expansion. The development of intranasal vaccines, particularly highlighted by the COVID-19 pandemic, also underscores the critical role of this delivery method in global health strategies. Key Insights: Market Growth: Understand the significant growth trajectory of the Liquid Delivery Devices segment, which is expected to reach US$38.0 Billion by 2030 with a CAGR of a 6.2%. The Powder Delivery Devices segment is also set to grow at 7.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $24.6 Billion in 2023, and China, forecasted to grow at an impressive 8.9% CAGR to reach $8.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as Acorda Therapeutics, Inc., Ferring Pharmaceuticals Inc, Bespak Europe Ltd., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 459 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $59.1 Billion Forecasted Market Value (USD) by 2030 $92.6 Billion Compound Annual Growth Rate 6.6% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Intranasal Drug Delivery - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) Intranasal Drug Delivery: A Prelude Leading Indications and APIs Amenable to Nasal Drug Delivery Regional Market Analysis Why Nasal Application is Garnering Notable Attention for Drug Delivery Limitations of Intranasal Drug Delivery Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range Drug Delivery Pathways Related to the Nasal Cavity Systemic delivery and Local Delivery Routes Differences between Systemic Delivery and Local Effects Challenges Involved In Formulating Nasal Drugs Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier Nose-to-Brain Drug Delivery: An Evolving Area of Interest Factors Inhibiting Nose-to-Brain Transportation of Drugs Bioavailability: An Important Facet of Intranasal Drug Delivery Traditional Vs. Advanced Intranasal Drug Formulation Types Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application Select FDA-Approved Nasal Products Compound (Trade Name) Indication Dosage Form Year Recent Market Activity MARKET TRENDS & DRIVERS Rise in Prevalence of COPD Drives Opportunities Global Prevalence of COPD: Percentage of Men and Women Affected by Age Group Pharmaceutical and Medical Device Companies Vie to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment Intranasal Corticosteroids : A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage Manufacturers Focus on Improved Nasal Delivery Platforms Controlled Release Technology is the Buzz Word Research on Nanocarrier-Based Intranasal Drug Delivery Systems Picks Up Pace Potential Role in Treatment and Management of Coronavirus Infection Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery Intranasal Therapeutics Delivery: A High Potential Method for Treating CNS Diseases Researchers Develop Nasal Spray Treatment for Parkinson's Disease Future Opportunities in CNS Space Intranasal Delivery of Stem Cells: A Primary Strategy for Treatment of CNS Disorders Intranasal Delivery of Stem Cells: Limitations Diagnosed Prevalence Cases of Parkinson's Disease Across Select Countries Intranasal Delivery of Peptide-Based Pharmaceuticals Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace Select List of Nasal Biologics Available in the Market Benefits of Bi-Directional Nasal Drug Delivery Rise in Interest in Preservative-free Nasal Spray Formulations Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies FOCUS ON SELECT PLAYERS (Total 77 Featured) Acorda Therapeutics, Inc. Ferring Pharmaceuticals Inc Bespak Europe Ltd. Breckenridge Pharmaceutical, Inc. Janssen Global Services LLC Hikma Pharmaceuticals PLC Biologische Heilmittel Heel GmbH Evoke Pharma, Inc. KemPharm, Inc. Impel NeuroPharma Actiza Pharmaceutical Pvt., Ltd. Covis Pharma H&T Presspart Manufacturing Ltd. Biomedica International Alchemy Pharmatech Ltd. For more information about this report visit https://www.researchandmarkets.com/r/4lr0vg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover, the radioimmunoassay market is expected to expand due to numerous ongoing research endeavors in this domain, partnerships between healthcare providers, researchers, and industry stakeholders, as well as strategic collaborations. These factors are poised to enhance the overall growth of the radioimmunoassay market from 2024 to 2030. LAS VEGAS, April 18, 2024 /PRNewswire/ -- DelveInsight's Radioimmunoassay Market Insights report provides the current and forecast market analysis, individual leading radioimmunoassay companies' market shares, challenges, radioimmunoassay market drivers, barriers, trends, and key market radioimmunoassay companies in the market. Key Takeaways from the Radioimmunoassay Market Report As per DelveInsight estimates, North America is anticipated to dominate the global radioimmunoassay market during the forecast period. As per the analysis, the global radioimmunoassay market was valued at USD 523.98 million in 2023. Notable radioimmunoassay companies such as DIAsource, MP BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science, Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher Corporation, and several others, are currently operating in the radioimmunoassay market. To read more about the latest highlights related to the radioimmunoassay market, get a snapshot of the key highlights entailed in the Global Radioimmunoassay Market Report Radioimmunoassay Overview Radioimmunoassay stands as a groundbreaking technique in the field of medicine and biology, revolutionizing the way researchers detect and measure tiny concentrations of biological substances. Developed in the 1950s by Dr. Rosalyn Yalow and Dr. Solomon Berson, this method uses the specific binding of antibodies to antigens to quantify substances like hormones, enzymes, and drugs. In RIA, a known radioactive substance is added to a sample containing the substance of interest. Then, an antibody that recognizes the substance binds to it, forming a complex. The amount of radioactivity in the complex is directly proportional to the concentration of the substance in the sample, allowing for highly sensitive measurements in the picomolar to nanomolar range. This remarkable precision has made RIA indispensable in diagnosing conditions such as thyroid disorders, diabetes, and various hormonal imbalances. Furthermore, the versatility of Radioimmunoassay extends beyond clinical settings, finding applications in research laboratories worldwide. Scientists rely on RIA to unravel intricate mechanisms of disease progression, monitor drug levels in patients, and investigate the role of hormones in physiological processes. Its ability to detect substances in minute quantities with high accuracy has propelled advancements in fields ranging from pharmacology to endocrinology, shaping our understanding of health and disease at a molecular level. Despite the emergence of newer technologies, the enduring legacy of Radioimmunoassay continues to underpin critical medical discoveries, demonstrating the enduring impact of this pioneering technique in modern science. Radioimmunoassay Market Insights In 2023, North America dominated the radioimmunoassay market, primarily due to several factors. These include a substantial patient population dealing with Sexually Transmitted Diseases (STDs), cancer, and other ailments, a robust environment for product development and launches, and the strong presence of key market players in the region. For instance, in 2019, it was estimated by the Centers for Disease Control and Prevention (CDC) that over 1.1 million people aged 13 and above were living with HIV in the US, while around 1.75 million new cancer cases were reported. Additionally, data from the American Thyroid Association in 2019 suggested that roughly 20 million Americans suffer from some form of thyroid disease, with over 12 percent expected to develop it during their lifetime. Furthermore, the US government's significant investment of USD 650 million in rapid diagnostic testing, as announced by the US Department of Health and Human Services in 2021, further underlines the favorable conditions for the radioimmunoassay market's growth in the region. Consequently, these factors are anticipated to drive the expansion of the radioimmunoassay market in North America throughout the forecast period spanning from 2024 to 2030. To know more about why North America is leading the market growth in the radioimmunoassay market, get a snapshot of the Radioimmunoassay Market Outlook Radioimmunoassay Market Dynamics The radioimmunoassay market dynamics have been steadily evolving, driven by a myriad of factors shaping the healthcare landscape. One of the key drivers is the growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and diabetes. As healthcare providers seek more efficient and accurate diagnostic tools, radioimmunoassay offers a reliable method for measuring minute quantities of substances, including hormones, enzymes, and drugs, in blood samples. This demand for precise diagnostic solutions has propelled the radioimmunoassay market forward, as clinicians rely on these tests for early detection, disease monitoring, and treatment optimization. Moreover, technological advancements have played a pivotal role in the expansion of the radioimmunoassay market. Automation and miniaturization have enhanced the efficiency of RIA tests, reducing turnaround times and improving accuracy. Additionally, the advent of novel biomarkers and reagents has widened the scope of applications for radioimmunoassay, further fueling market growth. With an increasing focus on personalized medicine, there is a rising need for tailored diagnostic approaches, a demand that the versatility and sensitivity of radioimmunoassays are uniquely positioned to fulfill. As such, the radioimmunoassay market continues to demonstrate resilience and promising prospects amidst the evolving landscape of healthcare needs and technological innovation. Get a sneak peek at the radioimmunoassay market dynamics @ Radioimmunoassay Market Dynamics Analysis Radioimmunoassay Market Assessment Radioimmunoassay Market Segmentation Radioimmunoassay Market Segmentation By Product Type: Analyzers And Reagents & Kits Radioimmunoassay Market Segmentation By Application: Research And Clinical Diagnostics Radioimmunoassay Market Segmentation By End User: Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical Industries, and Others Radioimmunoassay Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the radioimmunoassay market are set to emerge as the trendsetter explore @ Radioimmunoassay Companies Table of Contents Interested in knowing the radioimmunoassay market by 2030? Click to get a snapshot of the Radioimmunoassay Market Trends Related Reports Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene, among others. Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Intratumoral Cancer Therapies Market Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, along with emerging drugs and key intratumoral cancer therapies companies, including Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

The May 11th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases. COLUMBIA, Md., March 2, 2023 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, presents its prestigious Visionary Award to Doug Zarkin, Vice President and Chief Marketing Officer of Pearle Vision and Avi Kaner, Co-Owner of Morton Williams Supermarkets through its annual gala, Night for Sight. Taking place on Thursday, May 11 at 6 p.m. ET at The Lighthouse at Chelsea Piers in Manhattan, Night for Sight will celebrate beacons of the fashion, finance, and food industries. The Foundation will honor Doug Zarkin for his commitment to improving and supporting the vision industry through Pearle Vision, partnering with other nonprofits, providing high quality eyecare to children, as well as supporting others in the vision care space. Mr. Zarkin represents growth and compassion in the vision community and the Foundation is honored to recognize him at its annual gala in May. The Foundation is also proud to honor Avi Kaner for his leadership and commitment to the community through Morton Williams Supermarkets, his work as the elected Second Selectman (Deputy Mayor) of Westport, Connecticut, and his philanthropic efforts globally. Mr. Kaner embodies the Foundation's values of accessibility and equitability through his efforts, and they are excited to recognize him through Night for Sight. "The Foundation Fighting Blindness is excited to be partnering with Doug Zarkin and Avi Kaner through Night for Sight," said Peter Ginsberg, chief operating officer of the Foundation Fighting Blindness. "Their visionary leadership in their industries and their support of the Foundation's vision-saving efforts make them exemplary Visionary Award honorees. In celebrating these two leaders, the Foundation will highlight our shared goals and our efforts to be beacons of hope for those in the vision community." Thank you to Visionary Champion National Partner, Janssen Global Services, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Night for Sight Beacon Sponsor, Libertas Funding. Individual tickets to Night for Sight are $1,000, and Next Generation (under age 35) are $750. Sponsorship opportunities are available and range from $2,500 to $100,000. For ticket and sponsorship information, visit Give.FightingBlindness.org/NightforSight or contact Katie Van Benschoten at [email protected] or 212-961-6881. About the Foundation Fighting Blindness Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research. The Foundation has raised more than $891 million toward its mission to prevent, treat, and cure blindness caused by retinitis pigmentosa, macular degeneration, Usher syndrome and the spectrum of blinding retinal diseases. Visit FightingBlindness.org for more information. SOURCE Foundation Fighting Blindness